Large employers in the United States are increasingly reconsidering coverage for GLP-1 weight-loss medications such as Wegovy, Zepbound, and Foundayo as growing demand continues to drive healthcare costs higher. According to recent surveys, around 10% of employers that currently provide coverage for these drugs plan to discontinue the benefit in 2027, despite manufacturers introducing lower-priced options and oral alternatives to make treatments more accessible.
Industry experts note that the expanding popularity of GLP-1 medications, particularly the newly introduced weight-loss pills from Novo Nordisk and Eli Lilly, has attracted a broader patient base. While the oral medications are generally less expensive and appeal to individuals reluctant to use injections, the overall number of users continues to rise, offsetting any savings generated through lower drug prices. Employers are also concerned that they are not receiving the same pricing advantages available to consumers purchasing directly from drugmakers.
Healthcare consultants and benefits specialists predict that employer-sponsored coverage for obesity treatments may continue to decline in the coming years. Although the cost of individual treatments is expected to decrease, sustained market growth and long-term use of the medications are likely to keep GLP-1 drugs among the most significant healthcare expenses for employers, prompting many organizations to reassess their benefits strategies.
Pic Courtesy: google/ images are subject to copyright
